New logo! Rare Disease Cures Accelerator-Data and Analytics Platform has a new look! C-Path’s RDCA-DAP team is excited to unveil its new logo for the Rare Disease Cures Accelerator-Data and Analytics Platform
C-Path is proud to share our responses to the FDA draft guidance, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations The Clinical Outcomes Assessment (COA), Critical Path for Parkinson’s Digital Drug Development (3DT) Initiative, and Type 1 Diab
March 21, 2022 Recommendations to Optimize the Use of Volumetric MRI in Huntington’s Disease in Clinical Trials C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC) has published a new paper on volumetric MRI-based biomark
C-Path Welcomes ActiGraph C-Path is proud to welcome ActiGraph as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Compr
eCOA Consortium Announces Publication of Open Access Article C-Path’s eCOA Consortium is pleased to announce that “Measurement Comparability of Electronic and Paper Administration of Vi
Welcome uMotif C-Path is proud to welcome uMotif as the newest member of its Electronic Patient-Reported Outcome Consortium. Comprised of 15 fi
Critical Path for Parkinson’s Shares Internship Highlights from Mikayla Spott Critical Path for Parkinson’s is proud to highlight Mikayla Spott who joined the team as CPP’s first consortium intern i
C-Path’s Quantitative Medicine Team to Lead Trainee Tutorial at American Conference on Pharmacometrics On November 12, 2021 Jagdeep Podichetty, Director of Predictive Analytics within Quantitative Medicine program at Critical Path In
September 29, 2021 Volumetric MRI-Based Biomarkers in Huntington’s Disease: An Evidentiary Review C-Path's Huntington's Disease Regulatory Science Consortium (HD-RSC) has published a new paper on volumetric MRI-based...
